(Bloomberg) — Concordia Healthcare Corp. and Par Pharmaceutical Holdings Inc. agreed to settle U.S. claims that the companies engaged in anticompetitive conduct by agreeing not to compete in the sale of a generic prescription drug.

Concordia and Par entered in an unlawful agreement in which Concordia agreed not to sell a generic version of Kapvay, which treats attention deficit hyperactivity disorder, likely raising prices for consumers, the Federal Trade Commission said Tuesday.

"Concordia and Par reduced the number of competing generic Kapvay products available to consumers, depriving consumers of the lower prices that typically occur with generic competition," Debbie Feinstein, the director of the agency's competition bureau, said in a statement.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.